Compare Ginkgo Bioworks Holdings Inc (DNA) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Robinhood Markets, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B). The key difference: Robinhood Markets, Inc. is far larger — about 126× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Robinhood Markets, Inc. for 75 Days on average.
| DNA | HOOD | |
|---|---|---|
Market Cap | $763.64M | $96.21B |
Volume | 3,204,177 | 22,572,153 |
Sector | Health | Financials |
52-Week High | $15.83 | $152.46 |
52-Week Low | $5.48 | $65.16 |
Typical Hold Time | 7 Days | 75 Days |
Enterprise Value | $865.59M | $102.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
Robinhood (HOOD) trades at $107.01, down 2.28% today, amid a bullish technical setup with support at $105 and resistance at $109. The company reported strong 2025 results with revenue of $4.47 billion and net income of $1.88 billion, though Q1 2026 earnings missed expectations. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at boosting engagement.
Outlook remains positive with a consensus price target of $137.53, implying 28% upside, supported by 77% analyst buy ratings. Key risks include high valuation multiples (P/E 47.35) and reliance on retail trading growth, while regulatory scrutiny and market volatility pose challenges to sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
